increas risk ad failur downgrad neutral pt
invest summari downgrad neutral
overweight lower price target increas
pipelin base busi risk remov ad sale model
lower spinraza number reflect increas competit risk
move sidelin understand strategi growth
point like also view earlier program riski
lower probabl success across pipelin base case although
lower spinraza number slightli think could
downsid risk estim head earli may readout file
discontinu aducanumab morn take
probabl success entir ad franchis previou model
estim ad franchis revenu reflect po
note quick take think disappoint blow entir beta
amyloid hypothesi although still late-stag pipelin asset ad
elenbecestat think compani would need acquir
asset remain invest space
cautiou spinraza sma franchis revenu think
upcom competit data meet earli may key consider
like neg catalyst share slightli lower
estim still model mid-singl digit growth cut
spinraza revenu flat line dcf lower
suggest downsid risk competit dynam unfold
disclosur section may found page
use probability-adjust dcf valu share assum discount rate
model revenu roughli valuat base termin
risk price target neutral rate upsid includ lower expect
spinraza competit unforeseen pipelin success bolster sale
pipelin downsid risk includ greater-than-expect eros ms busi
brand gener competitor lower-than-expect spinraza revenu due increas
competit sma space neg headlin risk earli pipelin failur
revenu
amort acquir intang asset
total cost expens non-gaap
sale right
earn tax ebt non gaap
net equiti loss profit investe
non gaap net incom loss due non-controlling interest net tax
non gaap net incom net
net incom
non- reconcili
 restructur
exit donat cost
restructur sever
amort acquir intang asset reconcili
non-gaap amort acquir intang asset
amort acquir intang asset
gaap amort acquir intang asset
loss fair valu remeasur conting consider
incom tax effect relat reconcil item
loss equiti secur invest
fumapharma sharehold
net income/loss biosimilar jv
chang work capit
present valu flow
npv
npv termin valu
tv total
leader neurosci space commerci develop therapi neurology-bas diseas compani flagship
franchis multipl sclerosi ms includ market product tecfidera avonex plegridi tysabri collabor
genentech nc wholli own member roch group roch group nc entitl certain busi financi
right respect rituxan treatment non-hodgkin lymphoma chronic lymphocyt leukemia cll condit
gazyva indic treatment cll potenti therapi includ ocrevu
